Affiliation:
1. National Defense Medical College Hospital Department of Traumatology and Critical Care Medicine, , Tokorozawa City, Saitama, Japan
Abstract
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used to treat patients with type 2 diabetes mellitus but may induce diabetic ketoacidosis (DKA). Owing to their pharmacological mechanisms, they cause a different pathogenesis to that of typical DKA and require special attention in terms of blood glucose concentrations and acidosis. We describe a case of prolonged acidosis because of failure to immediately discover the use of an SGLT2 inhibitor. Compared with typical DKA, SGLT2 inhibitor-associated DKA requires earlier and longer glucose supplementation. SGLT2 inhibitors are specific aetiological factors in DKA, and their use should be suspected when the patient presents with mild hyperglycaemia or prolonged acidosis.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology,Parasitology
Reference12 articles.
1. A new hope in type 2 diabetes mellitus management: sodium-glucose cotransporter 2 inhibitors;Chaurasia;Cureus,2021
2. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study;Douros;Ann Intern Med,2020
3. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital;Papanastasiou;Hormones,2021
4. Effects of SGLT2 inhibitors on kidney and cardiovascular function;Vallon;Annu Rev Physiol,2021
5. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials;Yang;Medicine,2017